Chapter 1. Introduction


1.1. Report Description And Scope

1.2. Research Scope

1.3. Research Methodology


1.3.1. Market Research Process

1.3.2. Market Research Methodology

Chapter 2. Executive Summary


2.1. Global Hepatitis C Drug Market, 2016 2022 (USD Billion)

2.2. Global Hepatitis C Drug Market: Snapshot

Chapter 3. Hepatitis C Drug Market Dynamics


3.1. Introduction

3.2. Value Chain Analysis

3.3. Market Drivers


3.3.1. Global Hepatitis C Drug Market Drivers: Impact Analysis

3.3.2. Rise In Incidence of HCV Infection

3.3.3. Lack of Awareness

3.4. Market Restraints


3.4.1. Global Hepatitis C Drug Market Restraints: Impact Analysis

3.4.2. High Cost of Drugs

3.5. Opportunities


3.5.1. Covering Untapped Market

3.6. Porters Five Forces Analysis


3.6.1. Bargaining Power Of Suppliers

3.6.2. Bargaining Power Of Buyers

3.6.3. Threat From New Entrants

3.6.4. Threat From New Substitutes

3.6.5. Degree Of Competition

3.7. Market Attractiveness Analysis


3.7.1. Market Attractiveness Analysis, By End-user Segment

3.7.2. Market Attractiveness Analysis, By Regional Segment

Chapter 4. Global Hepatitis C Drug Market Competitive Landscape


4.1. Company Market Share, 2015 (Subject To Data Availability)

4.2. Strategic Development


4.2.1. Acquisitions Mergers

4.2.2. New Type Launch

4.2.3. Agreements, Partnerships, Collaborations And Joint Ventures

4.2.4. Research And Development, Regional Expansion

4.3. Type Portfolio

Chapter 5. Global Hepatitis C Drug Market End-user Analysis


5.1. Global Hepatitis C Drug Market: End-user Segment Overview


5.1.1. Global Hepatitis C Drug Market Revenue Share, By End-user, 2015 And 2021

5.2. Hospitals


5.2.1. Global Hepatitis C Drug Market for Hospitals, 2016 2022 (USD Billion)

5.3. Private labs


5.3.1. Global Hepatitis C Drug Market for Private labs, 2016 2022 (USD Billion)

5.4. Physician offices


5.4.1. Global Hepatitis C Drug Market for Physician offices, 2016 2022 (USD Billion)

5.5. Public health labs


5.5.1. Global Hepatitis C Drug Market for Public health labs, 2016 2022 (USD Billion)

5.6. Blood banks


5.6.1. Global Hepatitis C Drug Market For Blood banks, 2016 2022 (USD Billion)

Chapter 6. Global Hepatitis C Drug Market Regional Segment Analysis


6.1. Global Hepatitis C Drug Market: Regional Overview


6.1.1. Global Hepatitis C Drug Market Revenue Share, By Region, 2015 And 2021

6.2. North America


6.2.1. North America Hepatitis C Drug Market Revenue, By End-user, 2016 2022 , (USD Billion)

6.2.2. U.S.


6.2.2.1. U.S. Hepatitis C Drug Market Revenue, By End-user, 2016 2022 (USD Billion)

6.3. Europe


6.3.1. Europe Hepatitis C Drug Market Revenue, By End-user, 2016 2022 (USD Billion)

6.3.2. Germany


6.3.2.1. Germany Hepatitis C Drug Market Revenue, By End-user, 2016 2022, (USD Billion)

6.3.3. France


6.3.3.1. France Hepatitis C Drug Market Revenue, By End-user, 2016 2022, (USD Billion)

6.3.4. U.K.


6.3.4.1. U.K. Hepatitis C Drug Market Revenue, By End-user, 2016 2022 (USD Billion)

6.4. Asia Pacific


6.4.1. Asia Pacific Hepatitis C Drug Market Revenue, By End-user, 2016 2022 (USD Billion)

6.4.2. China


6.4.2.1. China Hepatitis C Drug Market Revenue, By End-user, 2016 2022 (USD Billion)

6.4.3. Japan


6.4.3.1. Japan Hepatitis C Drug Market Revenue, By End-user, 2016 2022 (USD Billion)

6.4.4. India


6.4.4.1. India Hepatitis C Drug Market Revenue, By End-user, 2016 2022 (USD Billion)

6.5. Latin America


6.5.1. Latin America Hepatitis C Drug Market Revenue, By End-user, 2016 2022 (USD Billion)

6.5.2. Brazil


6.5.2.1. Brazil Hepatitis C Drug Market Revenue, By End-user, 2016 2022 (USD Billion)

6.6. Middle East And Africa


6.6.1. Middle East And Africa Hepatitis C Drug Market Revenue, By End-user, 2016 2022 (USD Billion)

Chapter 7. Company Profile


7.1. Merck Co


7.1.1. Overview

7.1.2. Financials

7.1.3. Product Portfolio

7.1.4. Business Strategy

7.1.5. Recent Developments

7.2. Kenilworth


7.2.1. Overview

7.2.2. Financials

7.2.3. Product Portfolio

7.2.4. Business Strategy

7.2.5. Recent Developments

7.3. Roche


7.3.1. Overview

7.3.2. Financials

7.3.3. Product Portfolio

7.3.4. Business Strategy

7.3.5. Recent Developments

7.4. Basel GlaxoSmith


7.4.1. Overview

7.4.2. Financials

7.4.3. Product Portfolio

7.4.4. Business Strategy

7.4.5. Recent Developments

7.5. Gilead Sciences,


7.5.1. Overview

7.5.2. Financials

7.5.3. Product Portfolio

7.5.4. Business Strategy

7.5.5. Recent Developments

7.6. AbbVie


7.6.1. Overview

7.6.2. Financials

7.6.3. Product Portfolio

7.6.4. Business Strategy

7.6.5. Recent Developments

7.7. Johnson Johnson


7.7.1. Overview

7.7.2. Financials

7.7.3. Product Portfolio

7.7.4. Business Strategy

7.7.5. Recent Developments

7.8. Bristol-Myers Squibb


7.8.1. Overview

7.8.2. Financials

7.8.3. Product Portfolio

7.8.4. Business Strategy

7.8.5. Recent Developments